Isosteric antiherpes peptide derivatives
    13.
    发明授权
    Isosteric antiherpes peptide derivatives 失效
    等值抗原肽衍生物

    公开(公告)号:US5574015A

    公开(公告)日:1996-11-12

    申请号:US324434

    申请日:1994-10-17

    摘要: Disclosed herein are peptide derivatives of the formula A-B-D-CH.sub.2 CH{CH.sub.2 C(O)R.sup.1 }C(O)-NHCH{CR.sup.2 (R.sup.3)COOH}C(O)-E wherein A is a terminal group, for example an optionally substituted phenylalkanoyl, and B is a N-methyl amino acid residue; or A and B together form a saturated or unsaturated alkylaminocarbonyl; D is an amino acid residue; R.sup.1 is alkyl, cycloalkyl, a monosubstituted or a disubstituted amino; R.sup.2 is hydrogen or alkyl and R.sup.3 is alkyl, or R.sup.2 is hydrogen and R.sup.3 is phenylalkyl, or R.sup.2 and R.sup.3 are joined to form a cycloalkyl; and E is a terminal unit, for example, an alkylamino or a monovalent amino acid radical such as NHCH(alkyl)C(O)OH. The derivatives are useful for treating herpes infections.

    摘要翻译: 本文公开了式ABD-CH2CH(CH2C(O)R1} C(O)-NHCH(CR2(R3)COOH)C(O)-E的肽衍生物,其中A是末端基团,例如任选取代的苯基烷酰基 ,B为N-甲基氨基酸残基; 或A和B一起形成饱和或不饱和的烷基氨基羰基; D是氨基酸残基; R1是烷基,环烷基,单取代或二取代的氨基; R2是氢或烷基,R3是烷基,或R2是氢,R3是苯基烷基,或R2和R3连接形成环烷基; 并且E是末端单元,例如烷基氨基或单价氨基酸基团,例如NHCH(烷基)C(O)OH。 该衍生物可用于治疗疱疹感染。

    Process for key intermediates for HIV protease inhibitors
    16.
    发明授权
    Process for key intermediates for HIV protease inhibitors 失效
    HIV蛋白酶抑制剂关键中间体的方法

    公开(公告)号:US5550291A

    公开(公告)日:1996-08-27

    申请号:US434691

    申请日:1995-05-04

    CPC分类号: C07C213/08 Y02P20/55

    摘要: Disclosed herein is a stereospecific synthesis amenable to the large scale preparation of a hydrochloric acid addition salt of a chlorohydrin of the formula ##STR1## wherein R.sup.1 and R.sup.2 are amino protective groups and R.sup.3 is an amino acid side chain or a protected amino acid side chain. The synthesis involves reacting an aldehyde of the formula ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined hereinbefore with (chloromethyl)lithium at -20.degree. C. or below and contacting the resulting diastereoisomeric mixture of lithium alcoholates with aqueous hydrochloric acid to obtain a separable mixture of the hydrochloric acid addition salts of the chlorohydrin and its corresponding hydroxy diastereoisomer. The hydrochloric acid addition salt of the chlorohydrin is transformed readily into corresponding optionally amino-protected aminoepoxides; for example, 3(S)-(tert-butyloxycarbonylamino)-l,2(S)-epoxy-4-phenyl-butane.

    摘要翻译: 本文公开了一种立体特异性合成,其可以大规模制备下式的氯醇的盐酸加成盐:其中R1和R2是氨基保护基,R3是氨基酸侧链或被保护的氨基酸侧链 。 该合成包括使式(Ia)的醛,其中R 1,R 2和R 3如上文所定义,与(氯甲基)锂在-20℃或更低的温度下反应,并使所得到的醇锂与盐酸水溶液的非对映异构体混合物接触,得到 氯代醇的盐酸加成盐及其相应的羟基非对映异构体的可分离的混合物。 氯代醇的盐酸加成盐容易地转化成相应的任选氨基保护的氨基环氧化物; 例如,3(S) - (叔丁氧基羰基氨基)-1,2(S) - 环氧-4-苯基 - 丁烷。

    Antiherpes pentapeptide derivatives having a substituted aspartic acid
side chain
    17.
    发明授权
    Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain 失效
    具有取代的天冬氨酸侧链的反相五肽衍生物

    公开(公告)号:US5502036A

    公开(公告)日:1996-03-26

    申请号:US208168

    申请日:1994-03-09

    摘要: Disclosed herein are pentapeptide derivatives of the formula X--NR.sup.1 --CH(R.sup.2)--C(W)--NH--CR.sup.3 (R.sup.4)--C(W.sup.2)--NR.sup.5 --CH CH.sub.2 C(O)--Y!--C(W.sup.3)--NH--CR.sup.6 -- CR.sup.7 (R.sup.8)--COOH!--C(W.sup.4)--NH--CR.sup.9 (R.sup.10)--Z wherein X is a terminal group, for example, alkanoyl or phenylalkanoyl radicals, R.sup.1 is hydrogen, alkyl or phenylalkyl, R.sup.2, R.sup.4 and R.sup.10 are selected from amino acid or derived amino acid residues, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are hydrogen or alkyl or R.sup.7 and R.sup.8 are joined to form a cycloalkyl, W.sup.1, W.sup.2, W.sup.3 and W.sup.4 are oxo or thioxo, Y is, for example, an alkoxy or a mono or disubstituted amino, and Z is a terminal group, for example, COOH or CH.sub.2 OH. The derivatives are useful for treating herpes infections.

    摘要翻译: 本文公开了式X-NR1-CH(R2)-C(W)-NH-CR3(R4)-C(W2)-NR5-CH [CH2C(O)-Y] -C(W3)的五肽衍生物 -NH-CR 6 - [CR 7(R 8)-COOH] -C(W 4)-NH-CR 9(R 10)-Z其中X是末端基团,例如烷酰基或苯基烷酰基,R 1是氢,烷基或苯基烷基, R2,R4和R10选自氨基酸或衍生的氨基酸残基,R3,R5,R6,R7,R8和R9是氢或烷基或R7和R8连接形成环烷基,W1,W2,W3和W4分别为 氧代或硫代,Y是例如烷氧基或单或二取代的氨基,Z是末端基团,例如COOH或CH 2 OH。 该衍生物可用于治疗疱疹感染。

    Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus
    19.
    发明授权
    Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus 失效
    具有1,4-二氧代C,N-末端的抗原肽衍生物

    公开(公告)号:US5484771A

    公开(公告)日:1996-01-16

    申请号:US219600

    申请日:1994-03-29

    摘要: Described herein are peptide derivatives of the formula R.sup.1 NH--CO--Q--C(O)--NR.sup.2 --CH[CH.sub.2 C(O)--Y]--C(O)--NH--CH[CR.sup.3 (R.sup.4)--COOH]--C(W)--NH--CHR.sup.5 --Z wherein R.sup.1 is an optionally substituted alkyl or optionally substituted phenylalkyl, R.sup.2 is hydrogen or alkyl, R.sup.3 and R.sup.4 each independently is hydrogen or alkyl, or R.sup.3 and R.sup.4 are joined to form a cycloalkyl. R.sup.5 is alkyl, cycloalkyl or (cycloalkyl)alkyl, Q is a divalent radical, for example, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH-- or 1,2-cyclohexanediyl, which serves as a two carbon spacer. W is oxo or thioxo, Y is, for example, an alkoxy or a monosubstituted or disubsdtuted ammo, and Z is a terminal unit, for example, hydrogen, COOH or CH.sub.2 OH. The derivatives are useful for treating herpes infections.

    摘要翻译: 本文描述的是式R1NH-CO-QC(O)-NR2-CH [CH2C(O)-Y] -C(O)-NH-CH [CR3(R4)-COOH] -C(W)的肽衍生物 -NH-CHR 5 -Z,其中R 1是任选取代的烷基或任选取代的苯基烷基,R 2是氢或烷基,R 3和R 4各自独立地是氢或烷基,或者R 3和R 4连接形成环烷基。 R 5是烷基,环烷基或(环烷基)烷基,Q是二价基团,例如-CH 2 CH 2 - , - CH = CH-或1,2-环己二基,其用作二碳间隔基。 W是氧代或硫代,Y是例如烷氧基或单取代或未取代的氨基,Z是末端单元,例如氢,COOH或CH 2 OH。 该衍生物可用于治疗疱疹感染。